Kimia Biosciences Limited

Teneligliptin Hydrobromide Hydrate

TeneligliptinHydrobromide Hydrate

General Information:

Teneligliptinhydrobromide hydrate has been investigated for the treatment of Type 2 Diabetes Mellitus.This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids. It is a long-acting, orally bioavailable, pyrrolidine-based inhibitor of dipeptide peptidase 4 (DPP-4), with hypoglycemic activity. Teneligliptin may also reduce plasma triglyceride levels through a sustained increase in GLP-1 levels. It is vast growing molecule in Indian market.

Therapeutic Category.

TeneligliptinHydrobromide Hydrate falls under the Anti-Diabetic Category.

Product Characteristics:

IUPAC Name:

[(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone;hydrate;pentahydrobromide

Molecular Formula :

C44H67Br5N12O3S2

Molecular Weight :

1275.7 g/mol

Molecular Structure:

 

Mechanism of Action:

Teneligliptin acts on Incretin hormones, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released from enteroendocrine cells and enhance insulin secretion.Incretins are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), and have a very short half-life (t1/2) as a result. DPP-4 inhibitors increase the levels of active GLP-1 and GIP by inhibiting DPP-4 enzymatic activity; thus, in patients with diabetes, these inhibitors improve hyperglycemia in a glucose-dependent manner by increasing serum insulin levels and decreasing serum glucagon levels. Therefore, incretin-related agents such as DPP-4 inhibitors are promising drugs that can decrease glucose fluctuations in diabetic patients and have emerged as a new class of antidiabetic.